<DOC>
	<DOCNO>NCT02971397</DOCNO>
	<brief_summary>This pilot clinical trial study side effect cytarabine daunorubicin hydrochloride see well work treat patient newly diagnose acute myeloid leukemia . Drugs use chemotherapy , cytarabine daunorubicin hydrochloride , work different way stop growth cancer cell , either kill cell , stop dividing , stop spreading , may safer heart .</brief_summary>
	<brief_title>Cytarabine Daunorubicin Hydrochloride Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety ( 3 month ) feasibility administer daunorubicin hydrochloride ( daunorubicin ) continuous infusion propose treatment regimen . SECONDARY OBJECTIVES : I . To assess safety ( 6 month ) administer daunorubicin continuous infusion propose treatment regimen . II . To assess treatment outcome ( include complete remission [ CR ] complete remission incomplete recovery [ CRi ] ) patient acute myeloid leukemia ( AML ) propose treatment regimen . III . To compare concordance magnetic resonance imaging ( MRI ) echocardiogram ( ECHO ) identify cardiac toxicity , ie reduction leave ventricular ejection fraction ( LVEF ) &gt; = 10 % ejection fraction ( EF ) = &lt; 50 % compare baseline LVEF . OUTLINE : INDUCTION : Patients receive cytarabine intravenously ( IV ) continuously 24 hour day 1-7 daunorubicin hydrochloride IV continuously 24 hour day 1-3 absence disease progression unacceptable toxicity . Patients undergo bone marrow aspirate biopsy day 14 . Patients bone marrow cellularity &gt; = 10 % &gt; 5 % leukemic blast , may receive second induction cytarabine IV continuously 24 hour day 1-5 daunorubicin hydrochloride IV continuously 24 hour day 1-2 absence disease progression unacceptable toxicity . CONSOLIDATION : Patients achieve remission receive cytarabine IV 3 hour every 12 hour day 1 , 3 , 5 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Patients core-binding factor ( CBF ) AML may receive 4 course therapy . After completion study treatment , patient follow minimum 30 day , 3 6 month , every 3 month thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients must morphologically confirm newly diagnose acute myelogenous leukemia ( AML ) blood bone marrow disease ; patient extramedullary disease absence bone marrow blood involvement eligible ; note : protocol use World Health Organization ( WHO ) diagnostic criterion AML ; patient acute promyelocytic leukemia ( APL , FrenchAmericanBritish Classification [ FAB ] , M3 ) blastic transformation chronic myelogenous leukemia ( CML ) eligible Eastern Cooperative Oncology Group ( ECOG ) performance status 03 Patients ECHO EF &gt; = 45 % within 28 day prior registration Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign Institutional Review Board ( IRB ) approve informed consent document Patients receive prior induction chemotherapy AML myelodysplastic syndrome ( MDS ) ; temporary prior measure apheresis hydroxyurea allow ; patient receive limited shortterm exposure ATRA ( trans retinoic acid ) AMLM3 ( acute promyelocytic leukemia ) rule , discontinue , eligible Patients receive investigational agent Patients prolong correct QT ( QTc ) interval ( &gt; 500 msec ) determine electrocardiogram ( EKG ) within 28 day prior registration Patients suitable cardiac MRI ; contraindication include : Intracranial metal , pacemaker , defibrillator , function neurostimulator device , implant electronic device Ferromagnetic cerebral aneurysm clip , intraorbital/intracranial metal Allergy gadolinium severe drug allergy Claustrophobia Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) Significant valvular disease , significant pulmonary disease require supplemental oxygen therapy History allergic reaction attribute compound similar chemical biologic composition daunorubicin cytarabine Patients documented central nervous system ( CNS ) involvement Patients know human immunodeficiency virus ( HIV ) positive ( + ) may eligible provide meet follow additional criterion within 28 day prior registration : CD4 cell &gt; = 500/mm^3 Viral load &lt; 50 copy HIV messenger ribonucleic acid ( mRNA ) /mm^3 combination antiretroviral therapy ( cART ) &lt; 25,000 copy HIV mRNA cART No zidovudine stavudine part cART Patients HIV+ meet criterion eligible study Patients uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue prior beginning treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>